Schedule a Meeting
Download Brochure
Table of Content
May 2025
Principal Consultant
Reviewed By
The global single nucleotide polymorphism (SNP) genotyping market size is calculated at USD 6.48 in 2024, grew to USD 7.24 billion in 2025, and is projected to reach around USD 19.48 billion by 2034. The market is expanding at a CAGR of 11.7% between 2025 and 2034.
| Metric | Details |
| Market Size in 2024 | USD 6.48 Billion |
| Projected Market Size in 2034 | USD 19.48 Billion |
| CAGR (2025 - 2034) | 11.7% |
| Leading Region | North America |
| Market Segmentation | By Technology, By Application, By Sample Type, By End User, By Region |
| Top Key Players | Invivoscribe, Veracyte, Thermo Fisher Scientific, 10X Genomics, Myriad Genetics, Illumina, Nanostring Technologies, QIAGEN, Roche, Oxford Nanopore Technologies, Personalis, Pacific Biosciences of California, Invitae, Bio-Rad Laboratories, Agilent Technologies |
One of the most frequently occurring genetic variations is the single-nucleotide polymorphisms (SNPs). As per the public SNP databases, the total number of SNPs surpasses 9 million. For connecting the sequence variations to phenotypic changes, SNPs are used as markers. By utilizing this application of SNPs, the human physiology, as well as the molecular basis of diseases, can be easily understood. Thus, for this reason, new rapid, affordable, and accurate approaches for SNP analysis are being developed. Thus, with the help of SNP genotyping techniques, various strategies, as well as detection methods, are being developed.
The data collected by the SNP genotyping method is complex to understand or interpret. Thus, with the help of AI integration as well as machine learning (ML) algorithms, the effects of the variants in the datasets can be understood more effectively. Hence, the algorithms such as neural networks, classification, ensemble, and regression are linked with genome-wide association studies (GWAS), which help in the collection of data related to the variants associated with diseases. Furthermore, it can be used in the identification of the significant single-nucleotide polymorphisms (SNP), detection of epistatic non-linear interaction, and integrated with other omics sets, as well as in disease risk assessment & prediction.
Growing Genetic Disorders
The genetic disorder within the population is rising. This, in turn, increases the demand for new diagnostic as well as treatment options. With the help of early diagnosis using SNP genotyping, early detection of risk factors is possible. Similarly, this helps in the effective management and treatment of genetic disorders. Furthermore, using SNP genotyping, precision medicine, as well as personalized medications depending on the characteristics of the patients, can be developed. Thus, all these factors drive the single nucleotide polymorphism (SNP) genotyping market growth, which in turn enhances patient outcomes.
The graph represents the total number of genetic disorders present. It indicates that there are different types of genetic disorders that are rising. Hence, it increases the demand for new diagnostic and treatment options for the effective management of these disorders. Thus, this in turn will ultimately promote the market growth.
Complex Data Analysis
The data acquired with the help of SNP genotyping is highly complex, which requires the help of experts in the field of genetics, statistics, as well as bioinformatics. If the data is misinterpreted, it may increase the errors associated with it, increasing the risk of misdiagnosis. Furthermore, it also requires highly sophisticated equipment during the analysis procedures. Thus, all these factors make the data complex to analyze, which in turn makes the process time-consuming.
Increasing Precision Medications
SNP genotyping has various applications in diagnosis as well as treatment options. At the same time, it helps in delivering personalized and precise medications to the patients. Hence, with the rising genetic disease, the demand for the same is increasing. It helps in identifying the genetic characteristics of individuals, which helps in the formation of personalized medications. Moreover, this data is being used to identify the drug metabolism in the patients. Therefore, this helps in formulating effective precision medicines depending on the genetic factors of the patient. Thus, this promotes the single nucleotide polymorphism (SNP) genotyping market growth.
For instance,
By technology type, the PCR-based genotyping segment dominated the market in 2024. The PCR-based genotyping provided fast results, along with enhanced accuracy and sensitivity. Moreover, it was affordable, which contributed to the market growth.
By technology type, the sequencing-based genotyping segment is estimated to grow significantly at a notable CAGR during the forecast period. The sequencing-based genotyping is being used in the studies of various diseases. At the same time, it is also being used in personalized therapies.
By application type, the pharmacogenomics segment dominated the market in 2024. The pharmacogenomics application provided various personalized treatment options for different diseases. Furthermore, different diagnostic options also enhanced the single nucleotide polymorphism (SNP) genotyping market growth.
By application type, the genetic testing segment is anticipated to be the fastest growing during the forecast period. The increasing awareness, as well as diseases, are increasing the use of genetic testing for early detection of genetic variations. Similarly, the affordability and accuracy also contribute to the same.
By sample type, the DNA segment dominated the market in 2024. The easy collection without any use of invasive techniques, as well as faster identification of polymorphism, as SNPs may be present in it, were the factors due to the DNA samples dominating the market.
By sample type, the RNA segment is anticipated to grow significantly during the forecast period. With the help of RNA samples, the mechanisms of various diseases can be easily understood. Moreover, the RNA-based biomarkers are also being used in the diagnosis and treatment of different diseases.
By end user, the pharmaceutical companies segment dominated the global single nucleotide polymorphism (SNP) genotyping market in 2024. The pharmaceutical companies provided various personalized treatment options along with new diagnostic techniques for genetic disorders with enhanced safety. This increased the patient outcomes.
By end user, the research labs segment is predicted to grow significantly during the forecast period. The research labs are developing various new precision medicines as well as diagnostic options, increasing the research conducted. This, in turn, is promoting the market growth.
North America dominated the single nucleotide polymorphism (SNP) genotyping market in 2024. North America consisted of well-developed research and development facilities. This increased the research conducted using SNP genotyping for various diagnostic as well as treatment options. This contributed to the market growth.
The research conducted in the U.S. is rising due to increasing demand for the use of early diagnostic methods for the detection of genetic mutations associated with cancer. This, in turn, is supported by the investments or the funding provided by the government.
Due to the increasing research and development in the industries as well as the institutes, the collaboration between them is also increasing. This contributes to the enhanced rates of the development of new diagnostic and treatment options using SNP genotyping.
Asia Pacific is estimated to host the fastest-growing single nucleotide polymorphism (SNP) genotyping market during the forecast period. Asia Pacific is facing a rise in the number of patients suffering from genetic disorders. This increases the demand for the use of SNP genotyping in the development of new screening and treatment approaches for the disease. This is also supported by the government, which enhances the market growth.
China is focused on the development of new diagnostic as well as treatment options to deal with the rising incidences of genetic disorders by utilizing SNP genotyping technologies. This is also supported by the government investments.
The rising genetic disorders are increasing the demand for early diagnosis and precision medications for their management in India. Thus, this increases the research and development procedure. Moreover, the government is also supporting it to make these approaches affordable.
Europe is expected to grow significantly in the single nucleotide polymorphism (SNP) genotyping market during the forecast period. Europe is experiencing a rise in the research conducted due to the increasing demand for the use of precision medication for the management of genetic disorders. It is further supported by the government investments and funding.
Germany is driven by the increasing demand for the use of precision medication. This, in turn, is increasing the research conducted in the industries as well as institutes. These are supported by the investments or funding provided by the government.
New research is being conducted in the UK to develop effective precision medication for various genetic disorders. Furthermore, the rule and regulation laid by the regulatory bodies helps in their development as well as their approval process.
By Technology
By Application
By Sample Type
By End User
By Region
May 2025
May 2025
May 2025
May 2025